{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:33:46Z","timestamp":1793144026010,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamaoncol.2019.2187","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T15:31:09Z","timestamp":1564068669000},"page":"1411","source":"Crossref","is-referenced-by-count":538,"title":["Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non\u2013Small Cell Lung Cancer Treated With Nivolumab"],"prefix":"10.1001","volume":"5","author":[{"given":"Suzanne L.","family":"Topalian","sequence":"first","affiliation":[{"name":"Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Bloomberg\u2013Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Bloomberg\u2013Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott N.","family":"Gettinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Section of Medical Oncology), Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber\/Harvard Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Powderly","sequence":"additional","affiliation":[{"name":"Carolina BioOncology Institute, Huntersville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"now with the Department of Medicine (Hematology and Oncology), Northwestern University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber\/Harvard Cancer Center, Boston, Massachusetts"},{"name":"now with the Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Leming","sequence":"additional","affiliation":[{"name":"The Christ Hospital Cancer Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, PLLC, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Antonia","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Hospital, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Hospital, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Hospital, Weill Cornell Medical College, New York, New York"},{"name":"now with the Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brent","family":"McHenry","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareeda","family":"Hosein","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Harbison","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Grosso","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Section of Medical Oncology), Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"coi190053r1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy.","volume":"318","author":"Topalian","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"coi190053r2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"7","key":"coi190053r3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi190053r4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00432-018-2707-4","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors in the treatment of non\u2013small cell lung cancer: a meta-analysis of randomized controlled trials.","volume":"144","author":"Luo","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"coi190053r5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma.","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"issue":"26","key":"coi190053r7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"coi190053r8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi190053r9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab.","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi190053r10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer.","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"coi190053r11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study.","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi190053r12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"coi190053r13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"coi190053r16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti\u2013PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi190053r17","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi190053r18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy.","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"4","key":"coi190053r19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi190053r20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"coi190053r21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer.","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"9","key":"coi190053r22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"coi190053r23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti\u2013PD-1 monoclonal antibody in patients with melanoma and NSCLC.","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"coi190053r24","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations.","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"coi190053r25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.v116:7","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"coi190053r26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11912-016-0509-x","article-title":"Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition.","volume":"18","author":"Friedman","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"69","key":"coi190053r27","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.v8i69","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"coi190053r28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40425-018-0395-x","article-title":"Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.","volume":"6","author":"Ho","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"coi190053r29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis.","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"coi190053r30","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi190053r31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.seminoncol.2018.07.003","article-title":"Immune-related adverse events are linked with improved progression-free survival in patients receiving anti\u2013PD-1\/PD-L1 therapy.","volume":"45","author":"Shafqat","year":"2018","journal-title":"Semin Oncol"},{"issue":"3","key":"coi190053r32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center.","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"coi190053r33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti\u2013PD-1 antibodies in cancer patients.","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi190053r34","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer.","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"coi190053r35","first-page":"36","article-title":"Nivolumab (nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.","author":"Topalian","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi190053r36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non\u2013small cell lung cancer trials: a meta-analysis.","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol"},{"key":"coi190053r37","first-page":"36","article-title":"4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"coi190053r38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2013small cell lung cancer treated with pembrolizumab: results from Phase I KEYNOTE-001 study.","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"coi190053r39","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi190053r40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"coi190053r6","unstructured":"ClinicalTrials.gov. A phase 1 study of nivolumab (BMS-936558) in subjects with advanced or recurrent malignancies (MDX1106-03). CA209-003; NCT00730639. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00730639. Accessed June 20, 2019."},{"key":"coi190053r14","unstructured":"Cancer Therapy Evaluation Program (CTEP) Introductory Guide MedDRA Version 15.1. MSSO-DI-6003-15.1.0; September 2012. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_15_1_English_0.pdf. Accessed on June 20, 2019."},{"key":"coi190053r15","unstructured":"Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Event v3.0 (CTCAE). Washington, DC: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Healthand Human Services; August 9, 2006. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed June 20, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2738775\/jamaoncology_topalian_2019_oi_190053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T22:37:56Z","timestamp":1570747076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2738775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.2187","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}